Tokyo and Chertsey, England (ots/PRNewswire) - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas"), today announced that Astellas Pharma Europe Ltd., ("Astellas Pharma Europe") has entered into a definitive agreement with Grünenthal under which Astellas Pharma Europe will transfer the exclusive rights for Qutenza(TM) (capsaicin 8% patch) in Europe, Middle East and Africa to Grünenthal. (Logo: ...
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma Inc. (TSE:4503), is pleased to announce that Mr Yukio Matsui has been appointed as President of EMEA Operations, with responsibility for the company's commercial operations in Europe, the Middle East and Africa. Yukio will assume his new position on 1st April 2016. Since ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - Experts say the knock-on effect of lack of planning for later life, as highlighted in poll conducted for this year's ASTELLAS INNOVATION DEBATE[TM],will further impact upon stretched NHS resources Results from a new survey for the annual Astellas Innovation Debate have ...
Chertsey, England (ots/PRNewswire) - Poll conducted in advance of this year's ASTELLAS INNOVATION DEBATE(TM) also demonstrates public are open to an additional 'health tax' to support improved NHS services, but clinicians fear additional charges will hit the poorest hardest Although the NHS is ranked as one of the ...
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced the European Commission has granted approval for a label extension for QUTENZA[TM] (capsaicin 8% patch) to include the treatment of adult diabetic patients with peripheral neuropathic pain, either alone or in combination with other ...
Chertsey, England (ots/PRNewswire) - $150,000 Grant will be awarded on Monday 14th September The Astellas European Foundation has announced the shortlist for the 2015 Transplantation Grant. The Grant programme supports medical and related scientific programmes which contribute to advancements in transplantation. The six programme finalists are led by institutions ...
Chertsey, England (ots/PRNewswire) - - Results from Phase 1/2 trial investigating drug candidate for rare, aggressive blood cancer announced at European Hematology Association Congress; Phase 3 trial planned for late 2015 Astellas Pharma Europe today announced that preliminary data from a Phase 1/2 trial[a] on the ...
Astellas Pharma Europe Ltd. and Medivation, Inc.
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. and Medivation, Inc. announced that two enzalutamide abstracts will be presented at the annual European Association of Urology (EAU) Congress on March 24, 2015 in Madrid, Spain. (Logo: http://photos.prnewswire.com/prnh/20140522/689211 ) (Logo: ...
Chertsey, England (ots/PRNewswire) - $150,000 Grant will be awarded on Saturday 24th January The Astellas European Foundation has announced the shortlist for the Transplantation Grant. The Grant programme supports basic medical and related scientific programmes which contribute to advancements in transplantation. The five finalists are from Denmark, Germany, The ...
Chertsey, England (ots/PRNewswire) - $150,000 Grant will be awarded on Saturday 27th September The Astellas European Foundation has announced the shortlist for the 2014 Uro-Oncology Grant. The Grant programme supports basic medical and related scientific programmes which contribute to advancements in urological oncology. The five finalists include applications from The ...
Chertsey, England (ots/PRNewswire) - A recent study supported by an Astellas European Foundation Grant has identified potential therapeutic targets for transplantation treatment research. The study, carried out by Dr Nuria Lloberas, examined whether changing specific proteins in the body leads to a reduction in the immuno-inflammatory response thus lowering the risk of organ rejection. Dr Lloberas, from Hospital ...
Chertsey, England (ots/PRNewswire) - Dr Steffen Hartleif and Dr Ekkehard Sturm win $150,000 grant to support their research 'Safety and Tolerability of Immunomodulating Therapy with Mesenchymal Stem Cells in Paediatric Living-Donor Liver Transplantation' The Astellas European Foundation is delighted to announce that ...
Chertsey, England (ots/PRNewswire) - Institut Bergonié researchers identify six genes with potential to play significant role in fight against high grade form of disease Just four years after receiving an Astellas European Foundation Urology Prize Fund Award, researchers at France's Institut Bergonié have achieved their goal of identifying new gene targets that could ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - - For Healthcare and Business Media - Approval allows for more flexible approach to 8% capsaicin patch treatment of peripheralneuropathic pain The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - A new treatment, BETMIGA(TM) (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive bladder (OAB) symptoms in adults.[1] Mirabegron represents the first new class of oral treatment in OAB for over 30 years. Currently around half of patients discontinue OAB treatment after only three ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - Spectacular New Facilities, in Chertsey, Designed by Sir Norman Foster Astellas Pharma Europe Ltd. (APEL), the European Headquarters of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, today formally opens its new office in Hillswood Business Park, Chertsey. To accommodate the company's ...
Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for BETMIGA[TM] (mirabegron) for the symptomatic treatment of urgency, increased micturition ...